Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib

NCT00678119 is registered in ClinicalTrials.gov with Argos Therapeutics as lead sponsor.

NCT NCT00678119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00678119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib
Lead sponsor
Argos Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
May 31, 2012
Enrollment
25 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma